Potential therapy paradigms for Marfan syndrome

Bibliography

• MARFAN AB: Un cas de deformation congenitale des quatre membres plus prononce aux extremites caracterisse per allongement des os avec un certain degre d'amincissement. Bull. Mem. Soc. Med. Hop. Paris (1896) 13:220–226.
   Google Scholar
• GRAY JR, DAVIES, SJ: Marfan syndrome. J. Med. Genet. (1996) 33 (5):403–408.
   PubMed Web of Science ®Google Scholar
• TSIPOURAS P, KILPATRICK MW: Marfan syndrome. In: Molecular Genetics of Inherited Eye Disorders. Jay B &Wright A, (Eds.), Harwood Academic Publishers, London (1994):383–393.
   Google Scholar
• PYERITZ RE & MCKUSICK VA: The Marfan syndrome: diagnosis and management. New Engl. J. Med. (1979) 300(14):772–777.
   PubMed Web of Science ®Google Scholar
• MAUMENEE IH: The eye of the Marfan syndrome. Trans.Am. Opthalmol Soc. (1981) 79:684–733.
   PubMedGoogle Scholar
• KILPATRICK MW, HARTON GL, PHYLACTOU LA et al.: Preimplantation genetic diagnosis in Marfan syndrome. Fetal Diagn. Ther. (1996) 11(6)402–406.
   Google Scholar
• TSIPOURAS P: Marfan syndrome: light at the end of the tunnel. Am. J. Hum. Genet. (1990) 46(4):643–645.
   PubMed Web of Science ®Google Scholar
• HOLLISTER DW, GODFREY M, SAKAI LY & PYERITZ RE: Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. New Engl. J. Med. (1990) 323(3):152–159.
   PubMed Web of Science ®Google Scholar
• KAINULAINEN K, PULKKINEN L, SAVOLAINEN A, KAITILA I, PELTONEN L: Location on chromosome 15 of the gene defect causing Marfan syndrome. New Engl. J. Med. (1990) 323(14):935–939.
   PubMed Web of Science ®Google Scholar
• •Initial report of the localisation of the gene responsible for MFS.
   Google Scholar
• LEE B, GODFREY M, VITALE E et al.: Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature (1 9 9 1) 352(6333)330–334.
   Google Scholar
• TSIPOURAS P, DEL MASTRO R, SARFARAZI M et al.: Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5. The International Marfan Syndrome Collaborative Study. New Engl. J. Med. (1992) 326(14):905–909.
   PubMed Web of Science ®Google Scholar
• DIETZ HC, CUTTING GR, PYERITZ RE et al.: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene [see comments]. Nature (1991) 352(6333)337–339.
   Google Scholar
• •First reported identification of an FBN1 mutation in MFS patients.
   Google Scholar
• DIETZ HC, PYERITZ RE: Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum. Mol. Genet. (1995) 4 Spec No:1799-1809.
   Google Scholar
• ••A concise summary of FBN1 mutations identified in patientswith MFS and related conditions.
   Google Scholar
• RAMIREZ F: Fibrillin mutations in Marfan syndromeand related phenotypes. Curr. Opin. Genet. Dev. (1996) 6 (3):309–315.
   PubMed Web of Science ®Google Scholar
• AOYAMA T, TYNAN K, DIETZ HC, FRANCKE U, FURTHMAYR H: Missense mutations impair intracel-lular processing of fibrillin and microfibril assembly in Marfan syndrome. Hum. Mol. Genet. (1993) 12:2135–2140.
   Google Scholar
• HEWETT DR, LYNCH JR, SMITH R, SYKES BC: A novel fibrillin mutation in the Marfan syndrome which could disrupt calcium binding of the epidermal growth factor-like module. Hum. Mol. Genet. (1993) 2(0475–477.
   PubMed Web of Science ®Google Scholar
• HEWETT D, LYNCH J, CHILD A, FIRTH H SYKES B: Differ-ential allelic expression of a fibrillin gene (FBN1) in patients with Marfan syndrome. Am. J. Hum. Genet. (1994) 55(3):447–452.
   PubMed Web of Science ®Google Scholar
• GOTT VL, PYERITZ RE, CAMERON DE, GREENE PS, MCKUSICK VA: Composite graft repair of Marfan aneurysm of the ascending aorta: results in 100 patients. Ann. Thorac. Surg. (1991) 52 (0 :38–44.
   PubMedGoogle Scholar
• SHORES J, BERGER KR, MURPHY EA, PYERITZ RE: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. New Engl. J. Med. (1994) 330(19):1335–1341.
   PubMed Web of Science ®Google Scholar
• SILVERMAN DI, BURTON KJ, GRAY J et al.: Life expectancy in the Marfan syndrome. Am. J. Cardiol. (1995) 75(2):157–160.
   PubMed Web of Science ®Google Scholar
• SILVERMAN DI, GRAY J, ROMAN MJ et al.: Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J. Am. Coll. CardioL (1995) 26(4):1062–1067.
   PubMed Web of Science ®Google Scholar
• KILPATRICK MW, PHYLACTOU LA: Towards an RNA-based therapy for Marfan syndrome. Mol. Med. Today (1998) 4(9):376–382.
   PubMedGoogle Scholar
• •An alternative review of the potential for ribozymes to be beneficial in the therapy of MFS.
   Google Scholar
• ELDADAH ZA, BRENN T, FURTHMAYR H, DIETZ HC: Expression of a mutant human fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. J. Clin. Invest. (1995) 95(2):874–878.
   PubMed Web of Science ®Google Scholar
• PEREIRA L, ANDRIKOPOULOS K, TIAN J et al.: Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nature Genet. (1997) 17(2):218–222.
   PubMed Web of Science ®Google Scholar
• ••A report of transgenic mice that supports a role for fibrillin-1in tissue homeostasis rather than organogenesis.
   Google Scholar
• GUERRIER-TAKADA C, GARDINER K, MARSH T, PACE N, ALTMAN S: The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 35:849–857.
   PubMed Web of Science ®Google Scholar
• CECH TR, ZAUG AJ, GRABOWSKI PJ: In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell (1981) 27(3 Pt 2)487–496.
   Google Scholar
• BREAKER RR, JOYCE GF: A DNA enzyme with Mg(24dependent RNA phosphoesterase activity. Chem. Biol. (1995) 2(10655–660.
   Google Scholar
• ROBERTUS JD, LADNER JE, FINCH JT et al.: Structure of yeast phenylalanine tRNA at 3 A resolution. Nature (1974) 250(467):546–551.
   PubMedGoogle Scholar
• LADNER JE, JACK A, ROBERTUS JD et al.: Structure of yeast phenylalanine transfer RNA at 2.5 A resolution. Proc. Natl. Acad. Sci. USA (1975) 72(11):4414–4418.
   Google Scholar
• LATHAM JA, CECH TR: Defining the inside and outside of a catalytic RNA molecule. Science (1989) 245 (4915):276–282.
   PubMed Web of Science ®Google Scholar
• SYMONS RH: Self-cleavage of RNA in the replication of small pathogens of plants and animals. Trends Biochem. Sci. (1989) 14(10:445–450.
   PubMedGoogle Scholar
• SYMONS RH: Small catalytic RNAs. Annu. Rev. Biochem. (1992) 61:641–671.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of hammerhead ribozymes.
   Google Scholar
• SHIMAYAMA T, NISHIKAWA S, TAIRA K: Generality of the NUX rule: kinetic analysis of the results of system-atic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry (1995) 34(11)3649–3654.
   Google Scholar
• SULLENGER BA, CECH TR: Ribozyme-mediated repair ofdefective mRNA by targeted, trans-splicing. Nature (1994) 371(6498):619–622.
   PubMed Web of Science ®Google Scholar
• CUENOUD B, SZOSTAK JW: A DNA metalloenzyme withDNA ligase activity. Nature (1995) 375(6532):611–614.
   PubMed Web of Science ®Google Scholar
• SANTORO SW, JOYCE GF: A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA (1997) 94(9):4262–4266.
   PubMed Web of Science ®Google Scholar
• ASAHINA Y, ITO Y, WU CH, WU GY: DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets. Hepatology (1998) 28(2):547–554.
   PubMed Web of Science ®Google Scholar
• SANTORO SW, JOYCE GF: Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry (1998) 37 (38):13330–13342.
   PubMed Web of Science ®Google Scholar
• MILLINGTON-WARD S, O'NEILL B, TUOHY G et al.: Strate-gems in vitro for gene therapies directed to dominant mutations. Hum. Mol Genet. (1997) 6(9):1415–1426.
   Google Scholar
• BIRIKH KR, HEATON PA, ECKSTEIN F: The structure, function and application of the hammerhead ribozyme. Euro. J. Biochem. (1997) 245(0:1–16.
   PubMedGoogle Scholar
• COUTURE LA, STINCHCOMB DT: Anti-gene therapy: the use of ribozymes to inhibit gene function. Trends Genet. (1996) 12(12):510–515.
   PubMed Web of Science ®Google Scholar
• PHYLACTOU LA, KILPATRICK MW, WOOD MJA: Ribozymes as therapeutic tools for genetic disease. Hum. Mol. Genet. (1998) 7(101649–1653.
   Google Scholar
• ••A review that specifically addresses the potential ofribozymes for the therapy of inherited diseases.
   Google Scholar
• HEIDENREICH 0, BENSELER F, FAHRENHOLZ A, ECKSTEIN F: High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleo-sides and phosphorothioates. J. Biol. Chem. (1994) 269(3):2131–2138.
   PubMed Web of Science ®Google Scholar
• PIEKEN WA, OLSEN DB, BENSELER F, AURUP H & ECKSTEIN F: Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science (1991) 253(5017):314–317.
   PubMed Web of Science ®Google Scholar
• MORGAN RA, ANDERSON WF: Human gene therapy. Annu. Rev. Biochem. (1993) 62:191–217.
   PubMed Web of Science ®Google Scholar
• LIEBER A, KAY MA: Adenovirus-mediated expression of ribozymes in mice. J. Virol. (1996) 70(5):3153–3158.
   PubMed Web of Science ®Google Scholar
• GRAHAM FL, PREVEC L: Manipulation of adenovirus vectors. In: Gene Transfer and Expression Protocols. Murray EJ (Ed.) The Humana Press, Inc. Clifton, NJ, USA (1990:109–128.
   Google Scholar
• WU GY, WU CH: Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. (1988) 263(29):14621–14624.
   PubMed Web of Science ®Google Scholar
• WAGNER E, ZENKE M, COTTEN M, BEUG H, BIRNSTIELML: Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA (1990) 87 (9):3410–3414.
   PubMed Web of Science ®Google Scholar
• COTTEN M, LANGLE-ROUAULT F, KIRLAPPOS,H et al.: Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc. Natl. Acad. ScL USA (1990) 87(10:4033–4037.
   Google Scholar
• ZATLOUKAL K, WAGNER E, COTTEN M et al.: Transferrinfection: a highly efficient way to express gene constructs in eukaryotic cells. Ann. NY Acad. ScL (1992) 660:136–153.
   PubMed Web of Science ®Google Scholar
• COTTEN M, WAGNER E, BIRNSTIEL ML: Receptor-mediated transport of DNA into eukaryotic cells. Methods Enzymol. (1993) 217:618–644.
   PubMed Web of Science ®Google Scholar
• KILPATRICK MW, PHYLACTOU LA, GODFREY M, WU CH, WU GY, TSIPOURAS P: Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. Hum. Mol. Genet. (1996) 5(12):1939–1944.
   PubMed Web of Science ®Google Scholar
• ••First report of the use of hammerhead ribozymes todown-regulate FBN1 gene expression.
   Google Scholar
• MONTGOMERY RA, DIETZ HC: Inhibition of fibrillin 1expression using Ul snRNA as a vehicle for the presen-tation of antisense targeting sequence. Hum. Mol. Genet. (1997) 6(4):519–525.
   PubMed Web of Science ®Google Scholar
• PHYLACTOU LA, TSIPOURAS P, KILPATRICK MW: Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Biochem. Biophys. Res. Commun. (1998) 249(3):804–810.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the potential for hammerhead ribozymes specifically downregulate mutant FBN1 gene expression.
   Google Scholar